Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: February 26, 2021)
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD
VISITS: 1 visit every 3 weeks, ongoing
PHASE: I
NCT ID: NCT04294628
Trastuzumab Deruxtican for Advanced Breast Cancer that is HER2 Positive, HER2 Expressing or Tests Positive for a HER2 Mutation
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fam-trastuzumab deruxtican-nxki (Enhertu®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">2 biopsies</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 expressing (HER2 low expressing) tumors are defined as IHC 1+ or IHC 2+/ISH-.</li> <li class="seamTextUnorderedListItem">Some tumors test positive for a HER2 gene mutation. </li> <li class="seamTextUnorderedListItem">Fam-trastuzumab deruxtican-nxki (Enhertu®) is an antibody-drug conjugate (ADC)--it uses a HER2 antibody to deliver a chemotherapy directly to cancer cells. It is approved for use in some people with metastatic HER2 positive breast cancer, but its use for HER2 expressing or HER2 mutated breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HER2 (ERBB2)</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04294628' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/her2-low-expressing-a-new-subcategory-of-her2-negative-breast-cancer/' target='_blank'>Metastatic Trial Talk: HER2-Low Expressing Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/enhertu' target='_blank'>Breastcancer.org: Fam-Trastuzumab-Deruxtecan-nxki</a> </li></ul>